Genocea Biosciences, Inc. (NASDAQ:GNCA) Stock - Is it Oversold?

Genocea Biosciences, Inc. (NASDAQ:GNCA) Stock - Is it Oversold?”

The mean target price as estimated by the analysts for the company has been recorded at $21.25.

The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. Some investors may only focus on the fundamentals of a company and completely ignore the technicals.

Traders will often use multiple moving averages to analyze a single security. Currently, Genocea Biosciences has an average volume of 499K. It has outperformed by 50.52% the S&P500.

Analysts expect Genocea Biosciences Inc (NASDAQ:GNCA) to report $-0.51 EPS on November, 2.They anticipate $0.06 EPS change or 13.33 % from last quarter's $-0.45 EPS. Genocea Biosciences, Inc. (GNCA) recently closed with rise of 4.23% to its 20-Day Simple Moving Average. Zacks Investment Research raised Genocea Biosciences from a "sell" rating to a "hold" rating in a report on Thursday, August 17th. Therefore 100% are positive. The rating was maintained by Needham on Tuesday, August 11 with "Buy". A sell rating on the other hand would be a recommendation to sell the security if now held, and avoid purchasing it on the open market. Genocea Biosciences has a average recommendation of "Buy" and an average price target of $10.23. The company presently has an average rating of "Buy" and an average target price of $14.52. The firm earned "Buy" rating on Tuesday, October 20 by Needham. As per Wednesday, August 9, the company rating was maintained by Cowen & Co. The firm has "Overweight" rating by PiperJaffray given on Thursday, September 29. Needham & Company LLC upgraded Genocea Biosciences from a hold rating to a buy rating and set a $12.00 price target for the company in a report on Monday, July 24th.

NASDAQ:GNCA) has reached an oversold level with an RSI (14) at 14.79.

Analysts recommendation for Genocea Biosciences, Inc.

More notable recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: which released: "Genocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data ..." on July 24, 2017, also with their article: "BRIEF-Genocea announces strategic shift to immuno-oncology and the development ..." published on September 25, 2017, published: "Genocea shares almost halved on shift in drug development, layoffs" on September 25, 2017. Finally, Stifel Nicolaus cut shares of Genocea Biosciences from a "buy" rating to a "hold" rating and dropped their price target for the company from $15.00 to $2.50 in a research note on Monday.

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. Dealing with market volatility is normal, but exploring all aspects of a company may be a good way to combat day to day volatility. The company uses its proprietary ATLAS™ antigen identification platform to build a pipeline of immunotherapies that now includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. It now has negative earnings.

Monday evening turned out to be a nightmare for Genocea Biosciences Inc (NASDAQ:GNCA) investors, after the drug maker announced that it has decided not to continue development of genital herpes treatment GEN-003, shifting to immuno-oncology and focusing on the development of neoantigen cancer vaccines.

Like this



27 September 2017
Investigation as bodies of husband and wife found in Rednal and Streetly
Mr Barnes posted a picture of the couple's wedding in May 2014 to his Facebook profile hours before the bodies were found. A man's body was found at a house in leafy Streetly, West Mids, in the early hours of yesterday morning.

27 September 2017
Equifax CEO Steps Down In The Wake Of Major Hack
The chief executive of Equifax is out after a massive data breach compromised the personal information of 143 million Americans. Rather than rallying on news of a CEO change, Equifax shares were lower by another 1.8% at $103.18 on Tuesday morning.

27 September 2017
United States slaps sanctions on 8 North Korean banks
Of the 26, 19 of them live in China, while three live in Russian Federation and two each in Libya and the United Arab Emirates. The designations by the Treasury Department are in line with a new executive order signed by President Donald Trump last week.

27 September 2017
Winston Peters tight-lipped as he returns to Wellington
The specials are expected to change the composition of parliament, but not in ways that would alter the big picture. When the leaders speak to Mr Peters it will be to confirm those arrangements so the serious deal-making can begin.

27 September 2017
United States hails Saudi Arabia U-turn on women drivers
Last month, Saudi police arrested an Arab woman after video circulated showing her driving a auto in the Eastern Province. A committee will be formed to look into how to implement the new order, which is slated to come into effect in June 2018.

27 September 2017
Full federal court to hear 'Making a Murderer' appeal
More federal judges heard arguments Tuesday on whether Brendan Dassey's murder confession was coerced by investigators. Steven Avery's former lawyer, Jerry Buting, was also at the hearing.

27 September 2017
Near term Outlook For QEP Resources, Inc. (NYSE:QEP)
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. ValuEngine cut QEP Resources from a "sell" rating to a "strong sell" rating in a research note on Friday, September 8th.

27 September 2017
LEGO Marvel Super Heroes 2: Official Inhumans Trailer
LEGO Marvel Super Heroes 2 will be arriving on the Xbox One, PS4, Nintendo Switch and PC on the 17th November. From the publisher, this is one of many worlds you can visit in the game.

27 September 2017
Brokers Change Their Target Price On Boardwalk Pipeline Partners LP (NYSE:BWP)
The sales growth rate for a stock is a measure of how the stock's sales per share (SPS) has grown over a specific period of time. The investment managers in our partner's database now have: 225.25 million shares, down from 228.34 million shares in 2017Q1.

27 September 2017
Golar LNG Partners LP Represen (NASDAQ:GMLP) Sees Significantly Lower Trading Volume
Blackstart Capital LP owned about 0.20% of Golar LNG Limited worth $4,414,000 at the end of the most recent reporting period. The firm has "Buy" rating given on Wednesday, May 31 by Maxim Group. 9/26/2017-Jefferies Group LLC Reiterated Rating of Buy.